Cargando…

IMRT clinical implementation: Prostate and pelvic node irradiation using Helios and a 120‐leaf multileaf collimator

Dynamic intensity modulated radiation therapy (IMRT) to treat prostate and pelvic nodes using the Varian 120‐leaf Millennium multileaf collimator (MLC) has been implemented in our clinic. This paper describes the procedures that have been undertaken to achieve this, including some of the commissioni...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, C. H., Mubata, C. D., Meehan, C. A., Bidmead, A. M., Staffurth, J., Humphreys, M. E., Dearnaley, D. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724541/
https://www.ncbi.nlm.nih.gov/pubmed/12383047
http://dx.doi.org/10.1120/jacmp.v3i4.2551
Descripción
Sumario:Dynamic intensity modulated radiation therapy (IMRT) to treat prostate and pelvic nodes using the Varian 120‐leaf Millennium multileaf collimator (MLC) has been implemented in our clinic. This paper describes the procedures that have been undertaken to achieve this, including some of the commissioning aspects of Helios, verification of the dynamic dose delivery, and quality assurance (QA) of the dose delivered to the patient. Commissioning of Helios included measurements of transmission through the 120‐leaf MLC, which were found to be 1.7% for 6 mV and 1.8% for 10 MV. The rounded leaf edge effect, known as the dosimetric separation, was also determined using two independent methods. Values of 1.05 and 1.65 mm were obtained for 6 and 10 MV beams. Five test patients were planned for prostate and pelvic node irradiation to 70 and 50 Gy, respectively. Dose and fluence verification were carried out on specially designed phantoms and dose points in the prostate were measured to be within 2.0% (mean 0.9%, s.d. 0.6%) of the calculated dose and in the nodes within 3.0% (mean 1.6%, s.d. 1.1%). Following the results of this commissioning and implementation study, we have started to treat men with a target volume including the prostate and pelvic nodes using Helios optimized dynamic IMRT delivery in a dose escalation protocol. PACS number(s): 87.53.–j, 87.90.+y